Iran is facing a growing healthcare challenge as medicine shortages deepen following a series of strikes that have damaged pharmaceutical facilities across the country. The situation has raised concerns among medical professionals and policymakers about the resilience of the national healthcare system amid prolonged conflict and supply disruptions.
According to reports citing Tehran-based pharmacist Pejman Naim, the availability of essential medicines has deteriorated significantly in recent weeks. The shortages, he said, are now being felt more acutely by patients who rely on regular treatment for chronic and life-threatening conditions.
The issue is closely linked to attacks attributed to the United States and Israel, which Iranian authorities say have targeted key components of the country’s pharmaceutical infrastructure. Since late February, approximately 25 facilities have reportedly been affected, including factories producing medications for cancer, cardiovascular diseases, anesthesia, and multiple sclerosis.
Among the facilities impacted is the Pasteur Institute of Iran, a major institution responsible for vaccine development and production. Damage to such facilities has compounded existing challenges within Iran’s pharmaceutical sector, which has already been under strain due to economic sanctions and limited access to imported materials.
“Some medications, such as those used to treat diabetes and cardiovascular conditions, are now extremely scarce,” Naim said. He noted that shortages were already present before the escalation of conflict, but the current situation has significantly worsened access for patients.
The scarcity of essential drugs has placed additional pressure on pharmacies, many of which are struggling to maintain adequate stock levels. Patients in need of routine medications are increasingly forced to search multiple locations or rely on informal networks to obtain treatment.
Despite these difficulties, Naim indicated that the situation remains manageable for now, largely due to adaptive measures taken by both the government and healthcare professionals. Authorities have introduced a hotline system designed to help citizens locate available medicines and identify pharmacies that still have supplies.
Pharmacists themselves have also established informal communication networks to share real-time information about drug availability. These networks enable quicker distribution of limited stock and help ensure that patients with urgent needs can be prioritized.
The Iranian government has taken steps to support the pharmaceutical sector, although its capacity to respond is constrained by broader economic conditions. Sanctions have restricted access to certain imported drugs and raw materials, making it difficult to sustain production levels even in facilities that remain operational.
The combined effect of infrastructure damage and supply chain limitations has created a complex challenge. While domestic production can cover some needs, specialized medications often depend on imported components that are now harder to obtain.
In addition to shortages, rising costs have become a significant concern. Naim reported that drug prices have increased sharply, placing essential treatments out of reach for some segments of the population. This trend reflects both reduced supply and increased production costs, as manufacturers face higher expenses for raw materials and logistics.
“The war has had a devastating impact on pharmacies,” he said. “Sales have dropped, while prices have surged, making it harder for people to afford the medicines they need.”
This economic pressure is particularly acute for patients with chronic illnesses, who require consistent access to medication over long periods. Interruptions in treatment can lead to serious health complications, further burdening the healthcare system.
Healthcare experts warn that prolonged shortages could have cascading effects, including increased hospital admissions and higher mortality rates for preventable conditions. The situation underscores the critical role of stable pharmaceutical supply chains in maintaining public health.
The government’s response has focused on both immediate mitigation and longer-term stabilization. In addition to the hotline system, efforts are being made to coordinate distribution more efficiently and prioritize critical medications.
Authorities have also emphasized the importance of domestic production, seeking to strengthen local manufacturing capabilities as a way to reduce dependence on imports. However, this strategy requires time and investment, particularly in areas where advanced technology or specialized ingredients are needed.
Internationally, the situation has drawn attention to the broader impact of conflict on civilian infrastructure. Iranian officials have repeatedly characterized the targeting of pharmaceutical facilities as a violation of international norms, describing such actions as war crimes.
These claims have added a legal and diplomatic dimension to the issue, as debates continue over the protection of healthcare infrastructure in conflict zones. Under international humanitarian law, medical facilities and services are generally afforded special protection, although enforcement remains a complex challenge.
For patients and healthcare providers on the ground, the immediate concern is access. The combination of shortages, rising prices, and logistical challenges has created an environment where obtaining basic treatment is increasingly difficult.
Pharmacists like Naim play a critical role in navigating this environment, acting as intermediaries between limited supply and urgent demand. Their efforts to coordinate and share information have become an essential part of the response to the crisis.
Looking ahead, there is cautious hope that conditions may improve if the current ceasefire holds or if tensions begin to ease. A reduction in hostilities could allow for the repair of damaged facilities and the restoration of supply chains.
Naim expressed optimism that drug availability could recover in the event of sustained stability. “We hope that during the ceasefire or after the conflict ends, access to medicines will improve and the market will begin to stabilize,” he said.
However, experts caution that recovery may take time, particularly given the scale of damage and the structural challenges facing the pharmaceutical sector. Rebuilding infrastructure, restoring production capacity, and reestablishing supply networks are complex processes that require coordinated efforts.
The situation in Iran highlights the broader vulnerability of healthcare systems in times of conflict. Disruptions to pharmaceutical production and distribution can have immediate and far-reaching consequences, affecting not only those directly impacted by violence but also patients with ongoing medical needs.
As the crisis continues to unfold, the focus remains on ensuring that essential medicines reach those who need them most. The balance between emergency response and long-term resilience will be critical in determining how effectively the system can recover.
For now, the growing shortage of medicines serves as a stark reminder of the interconnected nature of health, infrastructure, and stability. In a context where each element is under pressure, maintaining access to care becomes both a logistical and humanitarian priority.
